<code id='DD2E7A6FA7'></code><style id='DD2E7A6FA7'></style>
    • <acronym id='DD2E7A6FA7'></acronym>
      <center id='DD2E7A6FA7'><center id='DD2E7A6FA7'><tfoot id='DD2E7A6FA7'></tfoot></center><abbr id='DD2E7A6FA7'><dir id='DD2E7A6FA7'><tfoot id='DD2E7A6FA7'></tfoot><noframes id='DD2E7A6FA7'>

    • <optgroup id='DD2E7A6FA7'><strike id='DD2E7A6FA7'><sup id='DD2E7A6FA7'></sup></strike><code id='DD2E7A6FA7'></code></optgroup>
        1. <b id='DD2E7A6FA7'><label id='DD2E7A6FA7'><select id='DD2E7A6FA7'><dt id='DD2E7A6FA7'><span id='DD2E7A6FA7'></span></dt></select></label></b><u id='DD2E7A6FA7'></u>
          <i id='DD2E7A6FA7'><strike id='DD2E7A6FA7'><tt id='DD2E7A6FA7'><pre id='DD2E7A6FA7'></pre></tt></strike></i>

          Home / explore / fashion

          fashion


          fashion

          author:knowledge    Page View:79
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In